Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$288.18
-0.9%
$266.85
$211.43
$387.99
$8.06B0.95222,674 shs202,265 shs
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$3.93
+2.2%
$3.91
$2.55
$6.42
$200.01M1.163,652 shs881 shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
$19.50
$2.86B1.21.02 million shsN/A
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
-1.05%-1.72%+4.45%+31.31%-13.85%
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
+2.05%-4.38%+3.56%-11.50%-4.27%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
4.4183 of 5 stars
2.32.00.04.22.92.53.1
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
2.3261 of 5 stars
3.54.00.00.02.80.00.0
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
2.60
Moderate Buy$333.5015.73% Upside
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
3.00
Buy$9.00129.30% Upside
MorphoSys AG stock logo
MOR
MorphoSys
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MDG1, GNFT, MOR, and BIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/26/2025
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/19/2025
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$9.00
8/1/2025
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$387.00 ➝ $409.00
8/1/2025
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$245.00 ➝ $265.00
6/9/2025
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$260.00 ➝ $245.00
(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.57B3.04$10.06 per share28.66$263.42 per share1.09
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$76.77M2.56$0.07 per share57.19$1.50 per share2.62
MorphoSys AG stock logo
MOR
MorphoSys
$238.28M11.99N/AN/A$0.35 per share54.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
-$1.84B$11.7324.5723.15N/A12.50%4.01%2.82%10/29/2025 (Estimated)
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$1.63MN/A0.00N/AN/AN/AN/AN/A9/22/2025 (Estimated)
MorphoSys AG stock logo
MOR
MorphoSys
-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/A

Latest MDG1, GNFT, MOR, and BIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/31/2025Q2 2025
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$1.93$2.61+$0.68$11.67$614.82 million$651.60 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
N/AN/AN/AN/AN/A
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
N/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
0.17
5.12
3.67
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
0.08
1.23
1.23
MorphoSys AG stock logo
MOR
MorphoSys
4.98
1.38
1.38

Institutional Ownership

CompanyInstitutional Ownership
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
65.24%
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
2.24%
MorphoSys AG stock logo
MOR
MorphoSys
18.38%

Insider Ownership

CompanyInsider Ownership
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
17.83%
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
4.20%
MorphoSys AG stock logo
MOR
MorphoSys
0.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
7,70027.06 million22.24 millionOptionable
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
12050.00 million47.90 millionNot Optionable
MorphoSys AG stock logo
MOR
MorphoSys
730150.62 million150.55 millionNot Optionable

Recent News About These Companies

MorphoSys takeover delivers phase 3 win for Novartis
Novartis to shut MorphSys sites amid pelabresib delay
Novartis sheds MorphoSys staff, sites after pelabresib delay
Novartis shutters MorphoSys sites, lays off staff
Novartis raises mid-term sales guidance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bio-Rad Laboratories stock logo

Bio-Rad Laboratories NYSE:BIO

$288.18 -2.53 (-0.87%)
As of 09/3/2025 03:58 PM Eastern

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

GENFIT stock logo

GENFIT NASDAQ:GNFT

$3.82 -0.02 (-0.49%)
As of 09/3/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

MorphoSys stock logo

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)
As of 09/2/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.